ArticleNanotheranostics2022
Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy.
Open access · goldAbstract read
In one paragraph
Article in Nanotheranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 45 citations in OpenAlex.
- A mechanical reprogramming: synergistic tumor microenvironment normalization improves nano-immunotherapy delivery in prostate cancer via multiphysics modeling.Drug delivery and translational research · 2026Article
- Nanotechnology-enhanced CAR-T therapy strategies in cancer, aging, and autoimmune diseases.Journal of hematology & oncology · 2026Review
- Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer.Immunity, inflammation and disease · 2026Review
- Tumor-Targeted Delivery Therapy Based on PLGA Nanoparticles.Journal of functional biomaterials · 2026Review
- Emerging nanoimmunotherapeutic strategies for breast cancer.Discover oncology · 2026Review
- Nanomedicine delivery systems remodel the immunosuppressive microenvironment of colorectal cancer: synergistic strategies and mechanisms of targeted immune checkpoint inhibitors.Frontiers in immunology · 2026Review
- Salidroside-Based Nanomedicines for Triple-Negative Breast Cancer: From Molecular Mechanisms to Clinical Translation.Breast cancer (Dove Medical Press) · 2026Review
- PEGylated PLGA nanoparticles: unlocking advanced strategies for cancer therapy.Molecular cancer · 2025Review
- Breaking barriers: Smart vaccine platforms for cancer immunomodulation.Cancer communications (London, England) · 2025Review
- Advances in nanomaterials for precision drug delivery: Insights into pharmacokinetics and toxicity.BioImpacts : BI · 2025Review
- Combined Albumin Polyester Nanocarriers with Docetaxel for Effective Against Lung Cancer in Mice Model.International journal of nanomedicine · 2025Article
- Exosome-driven nano-immunotherapy: revolutionizing colorectal cancer treatment.Molecular biology reports · 2024Review
- cRGD-Conjugated Bilirubin Nanoparticles Alleviate Dry Eye Disease Via Activating the PINK1-Mediated Mitophagy.Investigative ophthalmology & visual science · 2024Article
- The drug release of PLGA-based nanoparticles and their application in treatment of gastrointestinal cancers.Heliyon · 2024Review
- Nanomaterials in Immunology: Bridging Innovative Approaches in Immune Modulation, Diagnostics, and Therapy.Journal of functional biomaterials · 2024Review
- Exploring treatment options in cancer: Tumor treatment strategies.Signal transduction and targeted therapy · 2024Review
- Injectable thermosensitive selenium-containing hydrogel as mesenchymal stem cell carrier to improve treatment efficiency in limb ischemia.Materials today. Bio · 2024Article
- Puerarin-Loaded Liposomes Co-Modified by Ischemic Myocardium-Targeting Peptide and Triphenylphosphonium Cations Ameliorate Myocardial Ischemia-Reperfusion Injury.International journal of nanomedicine · 2024Article
- Drug delivery methods for cancer immunotherapy.Drug delivery and translational research · 2024Review
- Enhanced tumor suppression in colorectal cancer via berberine-loaded PEG-PLGA nanoparticles.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Christina K LeeDivision of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Danielle F AtibalentjaDivision of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Lilian E YaoDivision of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Jangho ParkDivision of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Sibu KuruvillaDivision of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Dean W FelsherDivision of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Stanford University · US
Funding
Targeting the MYC Pathway for the Treatment of CancerR35CA253180 · NCI · STANFORD UNIVERSITY · PI DEAN W FELSHER · 2020 to 2026
$6.9MModeling and Predicting Therapeutic Resistance of CancerU01CA188383 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W, GAMBHIR, SANJIV S · 2014 to 2018
$3.2MPrognostic Metabolic Signatures of Cancers Through Mass Spectrometry ImagingR01CA184384 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W, ZARE, RICHARD N · 2014 to 2018
$2.7MProgram in Translational and Experimental HematologyT32HL120824 · NHLBI · STANFORD UNIVERSITY · PI MAJETI, RAVINDRA · 2014 to 2023
$2.4M(PQ7)Multi-scale Analysis of Tumor Microenvironment HeterogeneityR01CA208735 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W · 2017 to 2019
$2.2MCancer-Translational Nanotechnology Training Program (Cancer-TNT)T32CA196585 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W, RAO, JIANGHONG · 2015 to 2019
$1.8M30-parameter FACSymphony A3 flow cytometer for Shared Resource LabS10OD026831 · OD · STANFORD UNIVERSITY · PI NOLAN, GARRY P · 2019 to 2019
$510kNCI NIH HHS R01 CA184384NCI NIH HHS R01 CA208735NCI NIH HHS R35 CA253180NCI NIH HHS T32 CA196585NCI NIH HHS U01 CA188383NHLBI NIH HHS T32 HL120824NIH HHS S10 OD026831
Abstract
PubMed holds no abstract for this paper.
Indexed as
B7-H1 AntigenNanoparticlesAnimalsAntibodies, MonoclonalCell Line, TumorMicePolyestersPolyethylene GlycolsAntibodies, MonoclonalB7-H1 AntigenPolyesterspolyethylene glycol-poly(lactide-co-glycolide)Polyethylene GlycolsImmunotherapyMC38PD-L1PEG-PLGA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.